0001558370-22-008550.txt : 20220512 0001558370-22-008550.hdr.sgml : 20220512 20220512161629 ACCESSION NUMBER: 0001558370-22-008550 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220512 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc. CENTRAL INDEX KEY: 0001821323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474005543 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39746 FILM NUMBER: 22918022 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-336-7540 MAIL ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 sgtx-20220512x8k.htm 8-K
0001821323false00018213232022-05-122022-05-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2022

SIGILON THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39746

47-4005543

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

100 Binney Street, Suite 600, Cambridge, MA

02142

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 336-7540

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Trading

Name of each exchange

Title of each class

    

Symbol(s)

    

on which registered

Common Stock, $0.001 par value per share

SGTX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On May 12, 2022, Sigilon Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2022. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Form 8 K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

99.1

Press Release Issued by Sigilon Therapeutics, Inc. on May 12, 2022

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGILON THERAPEUTICS, INC.

By:

/s/ Rogerio Vivaldi Coelho, M.D.

Rogerio Vivaldi Coelho, M.D.

President and Chief Executive Officer

Date: May 12, 2022

EX-99.1 2 sgtx-20220512xex99d1.htm EX-99.1

Exhibit 99.1

A picture containing logo

Description automatically generated

SIGILON THERAPEUTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

On track to announce results from preclinical studies of SIG-005 in second half of 2022

Current cash position expected to fund operating plans into 2024

Cambridge, MA—May 12, 2022—Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the first quarter ended March 31, 2022 as well as certain other business highlights.

“This quarter, we continued to make headway with our strategic reprioritization plans. Due to our strengthened leadership team, we have advanced our clinical and corporate strategy, with a focus on the three strategic areas we previously outlined: MPS-1, diabetes and platform optimization,” said Rogerio Vivaldi, M.D., President and CEO of Sigilon. “To that end, the Sigilon team has been hard at work completing preclinical studies necessary to advance the clinical development of the SIG-005 program in patients with MPS-1, a lysosomal disease. We believe we remain on track to announce the results from our preclinical work in the second half of this year.”

Recent Program Highlights and Anticipated Milestones

The Company plans to report results from the SIG-005 preclinical studies designed to evaluate pericapsular fibrotic overgrowth (PFO) and strategies to mitigate PFO in humanized mice and non-human primates in the second half of 2022.

Sigilon expects to submit amendments to the Company’s Clinical Trial Applications (CTA) for SIG-005 for MPS-1 in the United Kingdom and Brazil in the second half of 2022.

In February, the Company presented preclinical data on the rare lysosomal diseases MPS-1 and MPS-6 at the 18th Annual WORLDSymposium™, held in San Diego.

In 2023, Sigilon expects to:
oInitiate its planned Phase 1/2 trial of SIG-005 for MPS-1 in the UK and Brazil;
oSubmit an Investigational New Drug (IND) application for MPS-1 in the United States; and
oConduct IND-enabling studies for SIG-002 in type 1 diabetes.


Corporate Updates

In March 2022, Sarah Yuan, Ph.D., joined the Company as Chief Technical Operations Officer (CTOO). Dr. Yuan brings more than 20 years of experience in process development, manufacturing sciences and CMC strategies from a broad range of leading biopharmaceutical companies. Prior to joining Sigilon, she held a number of leadership roles, most recently as Vice President of Process and Analytical Development at 2seventy bio, the oncology spinoff of bluebird bio.

Financial Results

Cash Position: Cash, cash equivalents and marketable securities were $103.1 million as of March 31, 2022 compared to $123.4 million as of December 31, 2021. The decrease was primarily driven by cash used for operating activities and capital expenditures. The Company expects that its cash, cash equivalents and marketable securities as of March 31, 2022 will support its currently anticipated operating expenses and capital expenditure requirements into 2024.

R&D Expenses: Research and development expenses were $11.6 million for the first quarter of 2022 compared to $16.0 million for the first quarter of 2021. The decrease in research and development expenses was primarily related to decreases in ongoing platform and pipeline development activities, personnel expenses and the SIG-007 program, which were partially offset by increases in the SIG-005 program. The decrease in platform and pipeline development, personnel expenses and SIG-007 and the increase in SIG-005 were primarily due to the Company’s reprioritization on the development of MPS-1, diabetes and platform optimization following the restructuring activities in December 2021.

G&A Expenses: General and administrative expenses were $5.0 million for the first quarter of 2022 compared to $5.5 million for the first quarter of 2021. The decrease in general and administrative expenses was driven by a reduction in personnel expenses that resulted from the restructuring that occurred in December 2021.

Net Loss: Net loss was $13.9 million for the first quarter of 2022 compared to $19.0 million for the first quarter of 2021. The decline in net loss as compared to the prior year was primarily due to savings realized in the Company’s operating expenses as a result of the Company’s updated strategy and corporate restructuring.

About Sigilon Therapeutics

Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or other therapeutic molecules needed by patients living with chronic diseases such as lysosomal diseases and diabetes. The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from immune rejection. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.


Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. These forward-looking statements address various matters, including the timing and results of our preclinical studies and our evaluation of PFO and mitigation strategies related thereto, the timing of our IND submission or CTA amendments for SIG-005, and the timing for the initiation of our Phase 1/2 clinical trial of SIG-005 in MPS-1, and the initiation and timing of IND-enabling studies for SIG-002, and our expected cash runway. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, that if we fail to achieve the expected financial and operational benefits of our corporate restructuring, our business and financial results may be harmed; the results of our investigation of the preliminary results of our Phase 1/2 clinical trial of SIG-001 in Hemophilia A or failure of SIG-005 in clinical development could adversely affect our business and may require us to discontinue or delay development of other product candidates, which are all based on the same SLTx platform; the SLTx platform consists of novel technologies that are not yet clinically validated for human therapeutic use and the approaches we are taking to discover and develop novel therapeutics are unproven; we may not be successful in our efforts to identify and develop product candidates; if clinical trials of our current and future product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates; if we are unable to obtain and maintain patent and other intellectual property protection our product candidates, our SLTx platform may be adversely affected, and the risks identified under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, and filed with the Securities and Exchange Commission (the “SEC”), as well as the other information we file with the SEC. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements, except as required by law. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.


Sigilon Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

(Unaudited)

March 31, 

December 31, 

    

2022

    

2021

Assets

 

  

 

  

Current assets:

 

  

 

  

Cash and cash equivalents

$

64,487

$

107,143

Marketable securities

38,618

16,213

Accounts receivable

 

62

 

59

Prepaid expenses and other current assets

 

6,234

 

2,729

Restricted cash—current

 

250

 

250

Total current assets

 

109,651

 

126,394

Property and equipment, net

 

3,689

 

3,994

Right-of-use assets

 

11,708

 

12,863

Restricted cash

 

1,118

 

1,118

Total assets

$

126,166

$

144,369

Liabilities and stockholders’ equity (deficit)

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

2,040

$

2,344

Accrued expenses and other current liabilities

 

8,060

 

8,998

Lease liabilities, current portion

 

4,407

 

4,845

Current portion of long-term debt

 

3,333

 

1,667

Deferred revenue from related party, current portion

 

19,206

 

17,034

Total current liabilities

 

37,046

 

34,888

Deferred revenue from related party, net of current portion

 

 

5,333

Lease liability, net of current portion

 

7,721

 

8,577

Long-term debt, net of discount

 

16,811

 

18,411

Total liabilities

$

61,578

$

67,209

Stockholders’ equity

 

  

 

  

Common stock, par value $0.001 per share; 175,000,000 shares authorized at March 31, 2022 and December 31, 2021; 32,399,257 and 32,359,895 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively

 

32

 

32

Preferred stock, par value $0.001 per share; 25,000,000 shares authorized at March 31, 2022 and December 31, 2021; no shares issued and outstanding at March 31, 2022 and December 31, 2021

 

 

Additional paid-in capital

 

292,043

 

290,377

Accumulated other comprehensive income

(389)

(10)

Accumulated deficit

 

(227,098)

 

(213,239)

Total stockholders’ equity

 

64,588

 

77,160

Total liabilities and stockholders’ equity

$

126,166

$

144,369


Sigilon Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(Unaudited)

Three Months Ended March 31, 

    

2022

    

2021

Revenue

 

  

 

  

Collaboration revenue

$

3,165

$

2,958

Operating expenses:

 

 

Research and development

 

11,618

 

15,985

General and administrative

5,024

5,540

Total operating expenses

 

16,642

 

21,525

Loss from operations

 

(13,477)

 

(18,567)

Other income (expense), net:

 

  

 

  

Interest income

 

64

86

Interest expense

 

(491)

(488)

Other income (expense)

 

45

(4)

Total other expense, net

 

(382)

 

(406)

Net loss

$

(13,859)

$

(18,973)

Net loss per share—basic and diluted

$

(0.43)

$

(0.60)

Weighted average common stock outstanding—basic and diluted

 

32,360,786

31,487,710

SOURCE: Sigilon Therapeutics, Inc.

Investor Contact
Robert Windsor, Jr., J.D.

VP, Head of Investor Relations

Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837

Media Contacts
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349

##


GRAPHIC 3 sgtx-20220512xex99d1001.jpg GRAPHIC begin 644 sgtx-20220512xex99d1001.jpg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end EX-101.SCH 4 sgtx-20220512.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 sgtx-20220512_lab.xml EX-101.LAB EX-101.PRE 6 sgtx-20220512_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 12, 2022
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date May 12, 2022
Entity File Number 001-39746
Entity Registrant Name SIGILON THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-4005543
Entity Address, Address Line One 100 Binney Street
Entity Address, Adress Line Two Suite 600
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 336-7540
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SGTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001821323
Amendment Flag false
XML 8 sgtx-20220512x8k_htm.xml IDEA: XBRL DOCUMENT 0001821323 2022-05-12 2022-05-12 0001821323 false 8-K 2022-05-12 SIGILON THERAPEUTICS, INC. DE 001-39746 47-4005543 100 Binney Street Suite 600 Cambridge MA 02142 617 336-7540 false false false false Common Stock, $0.001 par value per share SGTX NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( V"K%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " -@JQ4&ULS9+! M:L,P#(9?9?B>*'%9!R;UI6.G#08K;.QF9+4UBQ-C:R1]^SE9FS*V!]C1TN]/ MGT -!H5]I.?8!XKL*-V,ONV2PK 11^:@ !(>R9M4YD27F_L^>L/Y&0\0#'Z8 M X&LJC5X8F,-&YB 15B(0C<6%48RW,8<:WIX>7^9U"]O4^N/_RNPKZW;N_^ ML?%%4#?PZR[T%U!+ P04 " -@JQ4F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M V"K%0F%J )=P0 *,1 8 >&PO=V]R:W-H965T&UL MG9A=<^(V%(:OM[]"0SN==B8)MC"0; DSA) LL_F@,=OMM-,+80O0Q)9<60[P M[WMDP*:M.29[ S98KQZ=<_1*_EOTUTOZQ09DJ]VIMQ>-UP+!&/>&"L!(.O-S[D4625@./OG6BC MZ-,V/+S>J]_E@X?!S%C*ARKZ*D*SO&Y<-DC(YRR+S(M:?>*[ ;6M7J"B-/\D MJ^VSGM<@098:%>\: T$LY/:;K7>!.&S@'FE =PUHSKWM**>\98;U>UJMB+9/ M@YJ]R(>:MP8X(6U6?*/A7P'M3/]6!1D$V1 F0S*21I@-&+,5I$<$']F&N/2,4(?2?[=N EK!1PL^FLNUOHV/_#F8I49#;O]".FL5 MG;7RSKRZSJ:;A%<-'6]^>?X9@? *".\TB G70ME!AP126\F#*^U2\=V'#S7) M:!=H;51P%_\[$7'RE,4SKJN@< W'<<];5UVO@_!T"I[.*3PO?"%L$4#,GEA< M&2AG\CTT^AE,!E]F8Z'_MF/W[L=YY?QT_ "(>T6I-U32,P'=8B8^+WXX0PLN"\/(4PBE;DW$(Y2?F(MA.L>.9 MQA6][KGG..VVUT+PK@J\JU/P!F&H>9J>[2_( SQ'GF5EU'!%UW'(C9"2;R / M&OP3H72=TDZ==W*6F-.5JO137-'/!!1)QW$PO@.[=]_%-[1W4(%3M:HV>UQN MR.*9%N&"8W"EU[OT77#%_)AH]29D4)GE&LW' 896K@PN[NW_19NHU+"(_"&2 MHY.V1M&AKH>9LELN&"[N\WD.![ G.XZ""W3<+@92+@\N[NT/*H"83)9*8NM# MC4BKU3GOMCVTW,L%PL6=_:L6QG )@8GC3.X<+:VDPH7F+$K1(B]7 A=W:U]% M(A!&R 5YA/+6@D65/+A*+4_I^RYNTQ/-SP,(#X?YM=W\-E5, M-4JV/F&I]8T*7L_(#\X%;)-(PC1Y8U'&20+#39=,H]CE&D!QTYYJ%MKR\S?Q M3%467XV ?S_]'2,YV-SCYKR/&!FM@R63"WYT U_8DRET].3G'X4 M<[VP4;H'!;.T#I(P69U;7-#H#,U;Z?,4M^D]V9I !N%$2BQ0, M?,P^ /_/E3+[&WNP+][+]/\!4$L#!!0 ( V"K%2?H!OPL0( .(, - M >&PO9KEMWDOSAR+DCO9*ZW="C M<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+ M#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\ M0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9 M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I: M*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#S MGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[ MBK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1 MS;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG M_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P M%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/ MK O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( V"K%27 MBKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.sigilon.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports sgtx-20220512x8k.htm sgtx-20220512.xsd sgtx-20220512_lab.xml sgtx-20220512_pre.xml sgtx-20220512xex99d1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sgtx-20220512x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sgtx-20220512x8k.htm" ] }, "labelLink": { "local": [ "sgtx-20220512_lab.xml" ] }, "presentationLink": { "local": [ "sgtx-20220512_pre.xml" ] }, "schema": { "local": [ "sgtx-20220512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sgtx", "nsuri": "http://www.sigilon.com/20220512", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sgtx-20220512x8k.htm", "contextRef": "Duration_5_12_2022_To_5_12_2022_Qctp3XL_70mvbg4zHAf5TQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sgtx-20220512x8k.htm", "contextRef": "Duration_5_12_2022_To_5_12_2022_Qctp3XL_70mvbg4zHAf5TQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001558370-22-008550-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-008550-xbrl.zip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�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end